T

    Theravance Biopharma Inc (TBPH)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $17.04
    -0.01 (-0.06%)

    Market Cap: $885.22M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(18/40)
    Avg Surprise
    -12.24%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.20
    Range$0.20 - $0.20
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.32+60.0%
    60d ago$0.20+0.0%
    30d ago$0.20+0.0%
    7d ago$0.20+0.0%
    Current$0.20
    Revenue Consensus
    $22M
    Range$20M - $23M
    4 analysts
    Dec 31, 2026
    EPS Consensus$-0.15
    Range$-0.15 - $-0.15
    1 analysts
    Revenue Consensus
    $29M
    Range$16M - $56M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.15---
    Sep 26EST
    		-$0.20---
    Jun 26
    		$0.07$0.14-50.00%Miss-93.5%
    Mar 26
    		$0.01N/A-88.89%Miss+105.9%
    Dec 25
    		$0.06N/A-94.10%Miss+217.8%
    Sep 25
    		$0.04$-0.05+180.00%Beat+166.7%
    Jun 25
    		$1.08$0.67+61.19%Beat+930.8%
    Mar 25
    		$-0.17$-0.09-88.89%Miss-88.9%
    Dec 24
    		$-0.05$-0.08+39.86%Beat-267.0%
    Sep 24
    		$-0.06$-0.10+40.00%Beat-500.0%
    Jun 24
    		$-0.13$-0.07-85.71%Miss+0.0%
    Mar 24
    		$-0.09$-0.12+25.00%Beat+62.5%
    Dec 23
    		$0.03N/A+120.00%Beat+120.0%
    Sep 23
    		$-0.01N/A+88.89%Beat+90.0%
    Jun 23
    		$-0.13$-0.11-18.18%Miss-244.4%
    Mar 23
    		$-0.24$-0.20-20.00%Miss-9.1%
    Dec 22
    		$-0.15$-0.17+11.76%Beat+65.1%
    Sep 22
    		$-0.10$-0.04-150.00%Miss+78.3%
    Jun 22
    		$0.09$0.15-40.00%Miss+111.3%
    Mar 22
    		$-0.22$0.10-320.00%Miss+82.3%
    Dec 21
    		$-0.43$-0.33-30.30%Miss+53.3%
    Sep 21
    		$-0.46$-0.52+11.54%Beat+60.3%
    Jun 21
    		$-0.80$-0.88+9.09%Beat+20.0%
    Mar 21
    		$-1.24$-0.79-56.96%Miss-8.8%
    Dec 20
    		$-0.92$-1.02+9.80%Beat+21.4%
    Sep 20
    		$-1.16$-0.88-31.82%Miss-10.5%
    Jun 20
    		$-1.00$-0.88-13.64%Miss-38.9%
    Mar 20
    		$-1.14$-1.00-14.00%Miss+13.6%
    Dec 19
    		$-1.17$-1.13-3.54%Miss-27.2%
    Sep 19
    		$-1.05$-1.11+5.41%Beat+4.5%
    Jun 19
    		$-0.72$-1.24+41.94%Beat+5.3%
    Mar 19
    		$-1.32$-1.19-10.92%Miss-8.2%
    Dec 18
    		$-0.92$-1.06+13.21%Beat+43.9%
    Sep 18
    		$-1.10$-1.14+3.51%Beat+13.4%
    Jun 18
    		$-0.76$-1.23+38.21%Beat+40.2%
    Mar 18
    		$-1.22$-1.36+10.29%Beat+3.9%
    Dec 17
    		$-1.64$-1.16-41.38%Miss-20.6%
    Sep 17
    		$-1.27$-1.14-11.40%Miss-74.0%
    Jun 17
    		$-1.27$-1.17-8.55%Miss-
    Mar 17
    		$-1.27$-1.18-7.63%Miss-
    Dec 16
    		$-1.36$-1.05-29.52%Miss-
    Sep 16
    		$-0.73$-0.87+16.09%Beat-

    Key Metrics

    Valuation
    P/E Ratio95.20EV/EBITDA8.60x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin51.60%Operating Margin8.89%
    ROE20.90%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage33.20x
    Current Ratio13.54xQuick Ratio13.54x
    Trading Statistics
    Beta0.25Avg Volume517.83K
    52-Week High$21.0352-Week Low$13.08

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$17.01
    SMA 20$16.96
    SMA 50$16.96
    SMA 200$17.30
    EMA 10$17.01
    EMA 20$16.98
    EMA 50$16.89
    EMA 200$16.30

    MACD

    Line: 0.04Signal: 0.04Hist: 0.01

    ADX

    ADX: 29.4+DI: 26.0-DI: 8.5

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down12.0
    PSAR$17.01

    Bollinger Bands

    Upper Band$17.07
    Lower Band$16.85
    %B Position130%(Upper)
    Band Width0.84

    RSI (14-Day)

    Neutral
    61.3

    Momentum Oscillators

    Stoch %K70.9
    Stoch %D73.9
    Williams %R-31.7
    ROC (10d)0.7%
    Momentum0.12
    CCI (20d)115.6
    MFI (14d)66.3

    Volatility Measures

    ATR (14d)$0.07(0.4%)
    StdDev (20d)0.06
    Hist Vol2.5%(Low)

    Volume Flow

    VWAP$17.05
    OBV14.0M
    AD Line2.2M
    CMF (20d)-0.010

    Volume Metrics

    Avg Vol (20d)521.8K
    Vol Ratio0.7x
    VWMA (20d)$16.96

    Pivot Points

    R3$17.09
    R2$17.08
    R1$17.06
    Pivot Point$17.05
    S1$17.03
    S2$17.02
    S3$17.00

    Advanced Oscillators

    TSI17.76
    Ultimate Osc44.3
    KST5.40

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$20.73M$17.70M$45.89M$19.99M$26.20M$15.39M$18.75M$16.87M$14.26M$14.50M$17.57M$15.69M
    Cost of Revenue$0$0$1.51M$0$0$0$9.45M$0$0$0$8.31M$0
    Gross Profit$20.73M$17.70M$45.89M$19.99M$26.20M$15.39M$18.75M$16.87M$14.26M$14.50M$17.57M$15.69M
    Operating Expenses$29.01M$27.18M$25.88M$26.45M$28.92M$29.82M$27.95M$27.70M$29.96M$25.71M$23.80M$24.45M
    R&D$4.71M$5.83M$7.36M$8.11M$10.49M$11.45M$9.45M$9.27M$9.95M$8.97M$8.31M$8.31M
    SG&A$14.18M$17.72M$18.52M$18.33M$18.43M$18.37M$18.50M$16.88M$17.06M$16.74M$15.49M$16.14M
    Operating Income$-8,277,000$-9,483,000$20.01M$-6,455,000$-2,725,000$-14,434,000$-9,200,000$-10,837,000$-15,705,000$-11,207,000$-6,240,000$-8,760,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$582,000$573,000$663,000$643,000$643,000$630,000$644,000$629,000$623,000$609,000
    Income Before Tax$-4,791,000$-6,470,000$73.07M$-2,889,000$73.21M$-14,138,000$-8,939,000$-10,052,000$-15,221,000$-10,402,000$-5,016,000$-7,583,000
    Income Tax Expense$1.11M$-1,537,000$12.04M$-6,504,000$18.37M$-559,000$6.59M$2.65M$1.31M$1.26M$3.49M$1.37M
    Net Income$-5,898,000$-4,933,000$61.02M$3.62M$54.84M$-13,579,000$-15,527,000$-12,698,000$-16,529,000$-11,664,000$-8,510,000$-8,950,000
    EBITDA$-4,285,000$-5,635,000$23.85M$-1,680,000$74.80M$-12,443,000$-7,601,000$-8,660,000$-13,598,000$-8,594,000$-2,976,000$-6,037,000
    EBIT$-4,791,000$-6,470,000$23.65M$-2,316,000$73.87M$-13,495,000$-8,296,000$-9,422,000$-14,577,000$-9,773,000$-4,393,000$-6,974,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TBPH

    News

    Theravance Biopharma (TBPH) withholds 7,952 insider shares to cover taxes

    Theravance Biopharma's SVP, Brett A. Grimaud, had 7,952 Ordinary Shares withheld by the company on August 20, 2026, to satisfy tax obligations related to the vesting of restricted stock units. This transaction, valued at $16.95 per share, was not an open market trade. Following this, Grimaud directly holds 355,168 Ordinary Shares of Theravance Biopharma.

    Stock Titan•8/25/26•
    Neutral

    FDA says Theravance (TBPH) needs more data on nOH drug trial

    Theravance Biopharma (TBPH) reported that its Phase 3 CYPRESS study for ampreloxetine, a drug for symptomatic neurogenic orthostatic hypotension (nOH), did not meet its primary endpoint. Despite this, post hoc analyses suggested a more coherent treatment effect in a narrowly defined patient population. The FDA has indicated that additional pivotal trials are needed for approval, and Theravance is seeking further guidance on future study design.

    Stock Titan•8/25/26•
    Somewhat-Bearish

    Theravance Biopharma reports CYPRESS Phase 3 miss but FDA grants Type C meeting to discuss future trial

    Theravance Biopharma announced that its Phase 3 CYPRESS study for ampreloxetine missed its primary endpoint, showing no statistical significance in improving the OHSA composite score. However, post hoc analyses suggested a potential treatment signal in a specific symptomatic patient group, and physiological measures confirmed the drug's biological activity. The FDA has granted a Type C meeting to discuss the design of a potential future pivotal trial for ampreloxetine.

    TradingView•8/25/26•
    Neutral

    Theravance Biopharma (TBPH) CEO logs 20K-share tax withholding

    Theravance Biopharma's CEO, Rick E. Winningham, had 20,034 Ordinary Shares withheld on August 20, 2026, at $16.95 per share to cover tax obligations from vested restricted stock units. This transaction was directly with the issuer and not an open market trade. Following this, Winningham directly holds 1,611,022 Ordinary Shares, with additional indirect holdings.

    Stock Titan•8/25/26•
    Neutral

    Theravance Biopharma, Inc. Revenue Breakdown – NASDAQ:TBPH

    This article provides a revenue breakdown for Theravance Biopharma, Inc. (NASDAQ:TBPH). The company generated $107.46 million USD in revenue last year, primarily from its Human Therapeutics segment. The United States was the largest contributor to this revenue.

    TradingView•8/20/26•
    Somewhat-Bullish

    Frequently Asked Questions About TBPH

    Does TBPH pay dividends?
    Theravance Biopharma Inc (TBPH) does not currently pay a regular dividend.
    What is TBPH's P/E ratio?
    Theravance Biopharma Inc has a price-to-earnings (P/E) ratio of 95.20.
    What is TBPH's market cap?
    Theravance Biopharma Inc (TBPH) has a market capitalization of $885.22M with a current stock price of $17.04.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In